A Suzhou Puhe Biopharma Co. Ltd. patent reports new Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors described as potentially useful for the treatment of cancer.
Cyclin-dependent kinase 12 (CDK12)/cyclin K and CDK13/cyclin K inhibitors have been described in a Nanjing Sanhome Pharmaceutical Co. Ltd. patent and are reported to be potentially useful for the treatment of cancer.
Insilico Medicine Inc. has prepared and tested new spirocyclic mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer and viral infections.
Fermitin family homolog 1 (FERMT1), a member of the kindlin family of focal adhesion proteins, plays a pivotal role in mediating integrin-dependent cell adhesion and signaling. Scientists at Fujian Medical University (FJMU) assessed the functional significance of FERMT1 in glioma progression and stemness.
Researchers from Universite de Sherbrooke and University of California San Francisco presented the discovery and preclinical characterization of CCR2-targeting pepducin, PP-101.
Camptothecin derivatives reported to be useful for the treatment of cancer have been disclosed in a recent Genescience Pharmaceuticals Co. Ltd. patent.
Hainan Simcere Pharmaceutical Co. Ltd. has prepared bicyclic compounds acting as fibroblast growth factor receptor 3 (FGFR3) inhibitors potentially useful for the treatment of cancer.
Insilico Medicine Inc. has identified compounds acting as tyrosine-protein phosphatase non-receptor type 2 (PTPN2; TCPTP) inhibitors reported to be useful for the treatment of cancer and metabolic disease.
RSS
